Overview
What is Advancing Cancer Treatment?
Advancing Cancer Treatment (ACT) is a nonprofit organization situated in Moultonborough, New Hampshire. Their primary focus is on enhancing participant enrollment in prostate cancer clinical trials. ACT aims to establish a registry, encouraging a substantial number of prostate cancer patients to participate by submitting a straightforward saliva test, which provides their genetic information for research purposes. This registry would also provide an alert service, notifying them if any treatments or therapies match their profile, potentially improving their prognosis. ACT's mission is to transform the Washington, D.C. metropolitan area into a pioneer in boosting clinical trial enrollment, thereby expediting improved cancer care and treatment.
Official website here: www.actclinicaltrials.org
Is Advancing Cancer Treatment legitimate?
Advancing Cancer Treatment is a legitimate nonprofit organization registered as a 501(c)(3) entity. Advancing Cancer Treatment submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $0
Professional Fundraising Fees: $0
Other Salaries and Wages: $0
For more financial information, click here
Official website here: www.actclinicaltrials.org
What is the mission statement of Advancing Cancer Treatment?
Advancing Cancer Treatment (ACT) aims to lead the way in accelerating improved cancer care and treatment by increasing participation in clinical trials in the broader cancer research community. Currently, their focus is on prostate cancer clinical trials, with an objective to create a prostate registry. This registry aims to enroll a significant portion of prostate cancer patients by having them submit a simple saliva test for genetic information, which can be used in research. Additionally, ACT offers an alert service to these patients, notifying them if any treatments or therapies matching their genetic profile become available, potentially improving their outcomes.
Official website here: www.actclinicaltrials.org
Who is the CEO of Advancing Cancer Treatment?
Pamela Brown is the Director of Advancing Cancer Treatment.
Official website here: www.actclinicaltrials.org
What is the revenue of Advancing Cancer Treatment?
Advancing Cancer Treatment's revenue in 2022 was $3,010,183.
Official website here: www.actclinicaltrials.org
Who are the executives of Advancing Cancer Treatment and what are their salaries?
- Otis Brawley (Director)
- Robert Grossman (Director)
- Jenny B Aragon-Ching Md (Director)
- Donald L Trump Md (Director)
- Adam R Metwalli Md (Director)
- Pamela Brown (Vice President, Secretary) [Trustee/Director]
- David Brown (President, Treasurer) [Trustee/Director]
Official website here: www.actclinicaltrials.org
Where can I find the form 990 for Advancing Cancer Treatment?
The Advancing Cancer Treatment’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.actclinicaltrials.org
Learn more at the official website: www.actclinicaltrials.org
Mission Statement of Advancing Cancer Treatment
Advancing Cancer Treatment (ACT) is committed to driving innovation in cancer care and treatment in the field of clinical trials. Their mission is to position the Washington, D.C. metropolitan area as a leading hub for accelerating improved cancer treatment through enhanced clinical trial enrollment. ACT's primary goal is to advance cancer care by making significant strides in prostate cancer clinical trials. To achieve this, ACT is establishing a prostate registry, aiming to encourage a substantial portion of prostate cancer patients to participate. This participation is facilitated by a simple saliva test, which collects genetic information for research purposes. Additionally, ACT provides an alert service to patients, notifying them if any treatments or therapies that align with their genetic profile become available, potentially improving their outcome.
Impact
This information is meant to be a general summary of Advancing Cancer Treatment. Please take the time to review official sources before making any decisions based upon the content provided here.
Saturday, July 20, 2024
Advancing Cancer Treatment's impact lies in its mission to make the Washington, DC metropolitan area a leader in advancing clinical trial accrual for improved cancer care and treatment. By focusing on improving accrual to prostate cancer clinical trials, ACT aims to create a prostate registry that encourages a significant portion of patients to participate by submitting a simple saliva test for their genetic information. This initiative not only facilitates research but also provides an alert service to patients if any treatments or therapies match their profile, potentially changing their outcome. Through these efforts, Advancing Cancer Treatment is actively working towards enhancing cancer treatment options and outcomes in the region.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Organization Details
Founding Year
2018
Phone
(972) 935-6510
Principal Officer
Pamela Brown
Main Address
42 RUPPERT RD, MOULTONBOROUGH, NH, 03254
Website
www.actclinicaltrials.org
NTEE Category
Code: G12 - Disease
If you are a representative of Advancing Cancer Treatment and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.